Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RELA | Q04206 | 2/20 | 0.58 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.49 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.49 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | FADS1 | O60427 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1687354 | 1.00 | RELA (0.58) | RELANFE2L2CYP1A2CYP1A1CYP1B1 | |
| SCHEMBL1687392 | 0.89 | RELA (0.59) | RELANFE2L2CYP1A2CYP1A1CYP1B1 | |
| SCHEMBL1687390 | 0.89 | RELA (0.59) | RELANFE2L2CYP1A2CYP1A1CYP1B1 | |
| SCHEMBL30692042 | 0.86 | P4HB (0.47) | RELACYP1A2SMN1; SMN2MEN1LMNA | |
| SCHEMBL26535005 | 0.86 | P4HB (0.47) | RELACYP1A2SMN1; SMN2MEN1LMNA | |
| SCHEMBL2316051 | 0.81 | RELA (0.59) | RELANFE2L2CYP1A2CYP1A1CYP1B1 | |
| SCHEMBL17978233 | 0.81 | CYP1A1 (0.53) | RELANFE2L2CYP1A2CYP1A1CYP1B1 | |
| SCHEMBL19810852 | 0.81 | CYP1A1 (0.53) | RELANFE2L2CYP1A2CYP1A1CYP1B1 | |
| SCHEMBL2685486 | 0.81 | RELA (0.59) | RELANFE2L2CYP1A2CYP1A1CYP1B1 | |
| SCHEMBL28089618 | 0.79 | NFE2L2 (0.61) | RELANFE2L2CYP1A2CYP1A1CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2066640-B1 | 2-(1-OXO-1H-ISOQUINOLIN-2-YL) ACETAMIDE DERIVATIVES | ORGANON NV (NL) | 2011-09-07 | — | — | EP | disclosed |
| EP-2066640-B1 | 2-(1-OXO-1H-ISOQUINOLIN-2-YL) ACETAMIDE DERIVATIVES | ORGANON NV (NL) | 2011-09-07 | — | — | EP | disclosed |
| CN-101528703-B | 2-(1-oxo-1H-isoquinolin-2-yl) acetamide derivatives | ORGANON NV | 2011-09-07 | — | — | CN | disclosed |
| US-7906504-B2 | N-tert-Butyl-2-[3-(4-fluoro-3-methoxyphenyl)-1-oxo-7-(3-pyrrolidin-1-ylpropoxy)-1H-isoquinolin-2-yl]acetamide; 2-[3-(3-Chlorophenyl)-7-((S)-2-methyl-3-pyrrolidin-1-ylpropoxy)-1-oxo-1H-isoquinolin-2-yl]-N-isopropylacetamide; antidepressants; hypothalamo-pituitary-adrenal axis modulators | N.V. ORGANON (NL) | 2011-03-15 | — | — | US | disclosed |
| US-7906504-B2 | N-tert-Butyl-2-[3-(4-fluoro-3-methoxyphenyl)-1-oxo-7-(3-pyrrolidin-1-ylpropoxy)-1H-isoquinolin-2-yl]acetamide; 2-[3-(3-Chlorophenyl)-7-((S)-2-methyl-3-pyrrolidin-1-ylpropoxy)-1-oxo-1H-isoquinolin-2-yl]-N-isopropylacetamide; antidepressants; hypothalamo-pituitary-adrenal axis modulators | N.V. ORGANON (NL) | 2011-03-15 | — | — | US | disclosed |
| US-7906504-B2 | N-tert-Butyl-2-[3-(4-fluoro-3-methoxyphenyl)-1-oxo-7-(3-pyrrolidin-1-ylpropoxy)-1H-isoquinolin-2-yl]acetamide; 2-[3-(3-Chlorophenyl)-7-((S)-2-methyl-3-pyrrolidin-1-ylpropoxy)-1-oxo-1H-isoquinolin-2-yl]-N-isopropylacetamide; antidepressants; hypothalamo-pituitary-adrenal axis modulators | N.V. ORGANON (NL) | 2011-03-15 | — | — | US | disclosed |
| CN-101528703-A | 2-(1-oxo-1H-isoquinolin-2-yl) acetamide derivatives | ORGANON NV (NL) | 2009-09-09 | — | — | CN | disclosed |
| EP-2066640-A2 | 2-(1-OXO-1H-ISOQUINOLIN-2-YL) ACETAMIDE DERIVATIVES | N.V. Organon (NL) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008033757-A2 | 2-(1-OXO-1H-ISOQUINOLIN-2-YL) ACETAMIDE DERIVATIVES | N.V. ORGANON (NL) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008033757-A2 | 2-(1-OXO-1H-ISOQUINOLIN-2-YL) ACETAMIDE DERIVATIVES | N.V. ORGANON (NL) | 2008-03-20 | — | — | WO | disclosed |
| US-20080064678-A1 | 2-(1-OXO-1H-ISOQUINOLIN-2-YL)ACETAMIDE DERIVATIVES | N.V. ORGANON (NL) | 2008-03-13 | — | — | US | disclosed |
| US-20080064678-A1 | 2-(1-OXO-1H-ISOQUINOLIN-2-YL)ACETAMIDE DERIVATIVES | N.V. ORGANON (NL) | 2008-03-13 | — | — | US | disclosed |
| US-20080064678-A1 | 2-(1-OXO-1H-ISOQUINOLIN-2-YL)ACETAMIDE DERIVATIVES | N.V. ORGANON (NL) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064678-A1 | 2-(1-OXO-1H-ISOQUINOLIN-2-YL)ACETAMIDE DERIVATIVES | SULT2A1, ACAT2, HDAC6 | RELA 292/4885NFE2L2 155/4885CYP1A2 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.